{"id":"NCT03785366","sponsor":"Sebela Women's Health Inc.","briefTitle":"A PK Study Comparing VeraCept vs. ParaGard Intrauterine Devices (IUDs)","officialTitle":"A Randomized, Single-Blind, Comparative Bioavailability Study to Assess the Pharmacokinetic Properties of VeraCept速 Intrauterine Contraceptive vs ParaGard速 in Healthy, Post-Menarcheal Women","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-12-17","primaryCompletion":"2019-12-30","completion":"2024-08-01","firstPosted":"2018-12-24","resultsPosted":"2025-08-15","lastUpdate":"2025-08-15"},"enrollment":41,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"BASIC_SCIENCE"},"conditions":["Women at Risk for Pregnancy"],"interventions":[{"type":"DRUG","name":"VeraCept","otherNames":[]},{"type":"DRUG","name":"ParaGard","otherNames":["ParaGard T 380A"]}],"arms":[{"label":"VeraCept","type":"EXPERIMENTAL"},{"label":"ParaGard","type":"ACTIVE_COMPARATOR"}],"summary":"to Assess the Pharmacokinetic Properties of VeraCept速 Intrauterine Contraceptive vs ParaGard速 in Healthy, Post- Menarcheal Women","primaryOutcome":{"measure":"Relative Maximum Observed Total Serum Copper Concentration of VeraCept vs ParaGard (Cmax)","timeFrame":"Study Days Baseline (pre-insertion), 3, 8, 15, 22, 29, 57","effectByArm":[{"arm":"VeraCept","deltaMin":1210,"sd":202},{"arm":"ParaGard","deltaMin":1300,"sd":217}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":null,"sex":"FEMALE","healthyVolunteers":true,"inclusionCount":13,"exclusionCount":23},"locations":{"siteCount":2,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":20},"commonTop":["Intermenstrual bleeding","Dysmenorrhoea","Pelvic pain","Bacterial vaginosis","Upper respiratory tract infection"]}}